GMP plasmid DNA, or GMP Grade Plasmid DNA can be used for direct injection as DNA vaccines, gene therapy, or ex-vivo applications such as cell and gene therapies. Compare with other Plasmid DNA, GMP Plasmid has no animal derived enzymes or organic solvents.
The global GMP Plasmid DNA market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for GMP Plasmid DNA is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GMP Plasmid DNA is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for GMP Plasmid DNA in DNA Vaccines is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of GMP Plasmid DNA include Cobra Bio, Waisman Biomanufacturing, Gedeon Richter, Eurogentec, VGXI, PlasmidFactory, Kaneka, Delphi Genetics and Nature Technology Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for GMP Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GMP Plasmid DNA.
Report Scope
The GMP Plasmid DNA market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GMP Plasmid DNA market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GMP Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Cobra Bio
Waisman Biomanufacturing
Gedeon Richter
Eurogentec
VGXI
PlasmidFactory
Kaneka
Delphi Genetics
Nature Technology Corporation
LakePharma
Segment by Type
Standard
Ultra-Pure
Segment by Application
DNA Vaccines
Gene Therapy
Immunotherapy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GMP Plasmid DNA companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global GMP Plasmid DNA 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Standard
1.2.3 Ultra-Pure
1.3 麻豆原创 by Application
1.3.1 Global GMP Plasmid DNA 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 DNA Vaccines
1.3.3 Gene Therapy
1.3.4 Immunotherapy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global GMP Plasmid DNA 麻豆原创 Perspective (2019-2030)
2.2 GMP Plasmid DNA Growth Trends by Region
2.2.1 Global GMP Plasmid DNA 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 GMP Plasmid DNA Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 GMP Plasmid DNA Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 GMP Plasmid DNA 麻豆原创 Dynamics
2.3.1 GMP Plasmid DNA Industry Trends
2.3.2 GMP Plasmid DNA 麻豆原创 Drivers
2.3.3 GMP Plasmid DNA 麻豆原创 Challenges
2.3.4 GMP Plasmid DNA 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top GMP Plasmid DNA Players by Revenue
3.1.1 Global Top GMP Plasmid DNA Players by Revenue (2019-2024)
3.1.2 Global GMP Plasmid DNA Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global GMP Plasmid DNA 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by GMP Plasmid DNA Revenue
3.4 Global GMP Plasmid DNA 麻豆原创 Concentration Ratio
3.4.1 Global GMP Plasmid DNA 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by GMP Plasmid DNA Revenue in 2023
3.5 GMP Plasmid DNA Key Players Head office and Area Served
3.6 Key Players GMP Plasmid DNA Product Solution and Service
3.7 Date of Enter into GMP Plasmid DNA 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 GMP Plasmid DNA Breakdown Data by Type
4.1 Global GMP Plasmid DNA Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global GMP Plasmid DNA Forecasted 麻豆原创 Size by Type (2025-2030)
5 GMP Plasmid DNA Breakdown Data by Application
5.1 Global GMP Plasmid DNA Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global GMP Plasmid DNA Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America GMP Plasmid DNA 麻豆原创 Size (2019-2030)
6.2 North America GMP Plasmid DNA 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America GMP Plasmid DNA 麻豆原创 Size by Country (2019-2024)
6.4 North America GMP Plasmid DNA 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe GMP Plasmid DNA 麻豆原创 Size (2019-2030)
7.2 Europe GMP Plasmid DNA 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe GMP Plasmid DNA 麻豆原创 Size by Country (2019-2024)
7.4 Europe GMP Plasmid DNA 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific GMP Plasmid DNA 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific GMP Plasmid DNA 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific GMP Plasmid DNA 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific GMP Plasmid DNA 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America GMP Plasmid DNA 麻豆原创 Size (2019-2030)
9.2 Latin America GMP Plasmid DNA 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America GMP Plasmid DNA 麻豆原创 Size by Country (2019-2024)
9.4 Latin America GMP Plasmid DNA 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa GMP Plasmid DNA 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa GMP Plasmid DNA 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa GMP Plasmid DNA 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa GMP Plasmid DNA 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cobra Bio
11.1.1 Cobra Bio Company Detail
11.1.2 Cobra Bio Business Overview
11.1.3 Cobra Bio GMP Plasmid DNA Introduction
11.1.4 Cobra Bio Revenue in GMP Plasmid DNA Business (2019-2024)
11.1.5 Cobra Bio Recent Development
11.2 Waisman Biomanufacturing
11.2.1 Waisman Biomanufacturing Company Detail
11.2.2 Waisman Biomanufacturing Business Overview
11.2.3 Waisman Biomanufacturing GMP Plasmid DNA Introduction
11.2.4 Waisman Biomanufacturing Revenue in GMP Plasmid DNA Business (2019-2024)
11.2.5 Waisman Biomanufacturing Recent Development
11.3 Gedeon Richter
11.3.1 Gedeon Richter Company Detail
11.3.2 Gedeon Richter Business Overview
11.3.3 Gedeon Richter GMP Plasmid DNA Introduction
11.3.4 Gedeon Richter Revenue in GMP Plasmid DNA Business (2019-2024)
11.3.5 Gedeon Richter Recent Development
11.4 Eurogentec
11.4.1 Eurogentec Company Detail
11.4.2 Eurogentec Business Overview
11.4.3 Eurogentec GMP Plasmid DNA Introduction
11.4.4 Eurogentec Revenue in GMP Plasmid DNA Business (2019-2024)
11.4.5 Eurogentec Recent Development
11.5 VGXI
11.5.1 VGXI Company Detail
11.5.2 VGXI Business Overview
11.5.3 VGXI GMP Plasmid DNA Introduction
11.5.4 VGXI Revenue in GMP Plasmid DNA Business (2019-2024)
11.5.5 VGXI Recent Development
11.6 PlasmidFactory
11.6.1 PlasmidFactory Company Detail
11.6.2 PlasmidFactory Business Overview
11.6.3 PlasmidFactory GMP Plasmid DNA Introduction
11.6.4 PlasmidFactory Revenue in GMP Plasmid DNA Business (2019-2024)
11.6.5 PlasmidFactory Recent Development
11.7 Kaneka
11.7.1 Kaneka Company Detail
11.7.2 Kaneka Business Overview
11.7.3 Kaneka GMP Plasmid DNA Introduction
11.7.4 Kaneka Revenue in GMP Plasmid DNA Business (2019-2024)
11.7.5 Kaneka Recent Development
11.8 Delphi Genetics
11.8.1 Delphi Genetics Company Detail
11.8.2 Delphi Genetics Business Overview
11.8.3 Delphi Genetics GMP Plasmid DNA Introduction
11.8.4 Delphi Genetics Revenue in GMP Plasmid DNA Business (2019-2024)
11.8.5 Delphi Genetics Recent Development
11.9 Nature Technology Corporation
11.9.1 Nature Technology Corporation Company Detail
11.9.2 Nature Technology Corporation Business Overview
11.9.3 Nature Technology Corporation GMP Plasmid DNA Introduction
11.9.4 Nature Technology Corporation Revenue in GMP Plasmid DNA Business (2019-2024)
11.9.5 Nature Technology Corporation Recent Development
11.10 LakePharma
11.10.1 LakePharma Company Detail
11.10.2 LakePharma Business Overview
11.10.3 LakePharma GMP Plasmid DNA Introduction
11.10.4 LakePharma Revenue in GMP Plasmid DNA Business (2019-2024)
11.10.5 LakePharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Cobra Bio
Waisman Biomanufacturing
Gedeon Richter
Eurogentec
VGXI
PlasmidFactory
Kaneka
Delphi Genetics
Nature Technology Corporation
LakePharma
听
听
*If Applicable.
